Imcyse develops a next-generation Imotope™ platform that induces cytolytic CD4+ T cells to selectively eliminate disease-causing immune cells while sparing the rest of the immune system. The company is conducting a Phase 2 program in Type 1 Diabetes and has additional programs in Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, Celiac Disease and Rheumatoid Arthritis. Its Multiple Sclerosis candidate is expected to commence clinical trials by 2022. Imcyse is pursuing collaborations to advance its pipeline, including a license and collaboration with Pfizer on the RA program. The company intends to use recent proceeds to accelerate development of several first-in-class targeted disease‑modifying immunotherapeutics and to support expansion into the U.S. Imcyse was founded as a spin-off of the Catholic University of Leuven and is located in Liège, Belgium. Imcyse develops active targeted immunotherapies based on its Imotopes™ platform to treat and prevent severe chronic diseases caused by immune system disruptions. The platform administers specific modified peptides (Imotopes™) that generate cytolytic CD4 T‑cells to locally destroy the immune cells attacking the diseased organ. Led by Pierre Vandepapelière (CEO and CMO), the company plans to advance phase 2 development in type 1 diabetes and to initiate clinical trials in multiple sclerosis and other autoimmune diseases. It also intends to expand the technology to additional indications. Recently Imcyse secured €35M in funding—€28M equity, a €4.6M grant from the Walloon region (DGO6) and a €2M bank loan from Belfius—to support these clinical programs. Founded in 2010 as a spin‑off from KU Leuven and based in Liège, Belgium, Imcyse focuses on antigen‑specific immune modulation rather than broad immunosuppression.

Total raised

$65M

Funding rounds

4

Latest round

Series B

Latest activity

Feb 2021